PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
NCT ID: NCT07190469
Last Updated: 2025-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
80 participants
INTERVENTIONAL
2025-09-16
2029-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309
NCT01940133
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
NCT02078752
A Study of PSB205 in Subjects With Advanced Solid Tumors
NCT03986606
Study of PM060184 in Patients With Advanced Solid Tumors
NCT01299636
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of two parts: Phase 1A (dose escalation/expansion) and Phase 1B (dose optimization).
* Phase 1A will employ a dose-escalation design in patients with advanced solid tumors to assess the safety and tolerability of PQ203 as monotherapy and to establish a provisional Recommended Phase 2 Dose (RP2D). A dose-expansion component will further evaluate the provisional RP2D in one or more selected tumor types.
* Phase 1B will assess the provisional RP2D and further characterize safety, pharmacokinetics, and preliminary efficacy.
Endpoints:
* Primary Endpoints: Incidence of treatment-emergent adverse events (TEAEs) and determination of the RP2D.
* Secondary Endpoints: Pharmacokinetic profile of PQ203 and its payload (MMAE), and preliminary evidence of antitumor activity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PQ203
A Phase 1, first-in-human (FIH), multiple ascending dose study of the peptide drug-conjugate PQ203 to evaluate the safety, pharmacokinetics, tolerability and preliminary anti-cancer activity in patients with advanced cancers with solid tumors. Comprises up to 7 planned ascending dose cohorts with expansion of doses to identify recommended dose levels for testing in the Phase 1B Dose Optimization study. This is an open label study and all participants will receive PQ203.
PQ203
PQ203 is a peptide drug-conjugate given once weekly by intravenous infusion intended for the treatment of advanced solid tumor cancers including triple negative breast cancer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PQ203
PQ203 is a peptide drug-conjugate given once weekly by intravenous infusion intended for the treatment of advanced solid tumor cancers including triple negative breast cancer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically documented metastatic or locally advanced solid tumor malignancies having progressed through or being otherwise ineligible to receive approved standard-of-care therapies
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
* Documented presence of RECIST v1.1 measurable disease
* Adequate organ function confirmed by the following laboratory values obtained within 14 days of the first dose of PQ203:
Bone Marrow Function
* Absolute neutrophil count (ANC) ≥ 1.5 × 10e9/L
* Platelets \> 100 × 10e9/L
* Hemoglobin ≥ 9 g/dL
Hepatic Function
* AST, alanine transaminase ALT or ALP ≤ 2.5 × upper limit of normal (ULN); if liver metastases, then ≤ 5 × ULN
* Bilirubin ≤ 1.5 × ULN (\< 2 × ULN if hyperbilirubinemia is due to Gilbert's syndrome)
* Serum albumin ≥ 35 g/L (3.5 g/dL)
Renal Function
* Calculated creatinine clearance of ≥ 60 mL/min by the Cockcroft-Gault equation
* Urine protein \< 2+
Cardiac Function
• Left ventricular ejection fraction (LVEF) ≥ 50%
Other
* Understand and voluntarily sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)/Research Ethics Board (REB)-approved informed consent form prior to any study-specific evaluation.
* PT/PTT or INR \<1.2x upper limit of normal
* Non-surgically sterile men and women of child bearing potential must agree to use highly effective methods of contraception for at least 4 months beyond the final dose received.
* Toxicity of previous antitumor therapy has returned to Grade ≤1
Exclusion Criteria
* Blood transfusion within 14 days of study treatment
* Serious comorbid medical conditions such as heart, lung, kidney, liver, and brain disease that, in the opinion of the enrolling investigator, could interfere with study treatment
* Subjects with history of severe heart disease
* QTc interval using Fridericia's formula (QTcF) \> 470 ms
* Estimated or known weight \> 115 kg (253 lbs)
* Known/suspected pregnancy and/or lactation
* Diastolic blood pressure \< 60 mmHg or \>110 mmHg
* Uncontrolled intercurrent illness
* Long term care facility resident or prisoner
* Any prior receipt of a MMAE-containing drug
* Any prior receipt of a SORT1-targeting medication
* Participation in another clinical study investigating a drug or medical device or a neuro-interventional or surgical procedure that is not considered as standard care in the 30 days preceding study enrolment
* Treatment with any of the following:
* Chemotherapy or other systemic anti-cancer therapy ≤14 days or 5 half-lives (whichever is shorter) prior to first dose of study drug except for Nitrosoureas or mitomycins ≤42 days
* Major surgery ≤28 days from first dose of study drug
* Patients with a history of cerebrovascular accident within 6 months of planned first dose.
* Patients with clinically symptomatic ocular toxicities
* Patients with history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that require steroids, with current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
* Patients with active Grade \>1 peripheral neuropathy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ProteinQure Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MD Anderson Cancer Center
Houston, Texas, United States
NEXT Oncology
San Antonio, Texas, United States
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Sponsor website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PQ203-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.